Department of Clinical Research and Innovation (DRCI), Foch Hospital, 92150, Suresnes, France.
Centre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne, 80054, Amiens, France.
Transl Psychiatry. 2021 Apr 7;11(1):204. doi: 10.1038/s41398-021-01329-3.
Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized b-y recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear. Recent findings have shown that oxidative stress, inflammation, and the glutamatergic pathway play key roles in the causes of OCD. However, first-line therapies include cognitive-behavioral therapy but only 40% of the patients respond to this first-line therapy. Research for a new treatment is mandatory. This review focuses on the potential effects of lithium, as a potential therapeutic strategy, on OCD and some of the presumed mechanisms by which lithium provides its benefit properties. Lithium medication downregulates GSK-3β, the main inhibitor of the WNT/β-catenin pathway. The activation of the WNT/β-catenin could be associated with the control of oxidative stress, inflammation, and glutamatergic pathway. Future prospective clinical trials could focus on lithium and its different and multiple interactions in OCD.
强迫症（OCD）是一种神经精神疾病，其特征是反复出现的独特的强迫观念和/或强迫行为。其病因仍不清楚。最近的研究结果表明，氧化应激、炎症和谷氨酸能通路在 OCD 的病因中起关键作用。然而，一线治疗包括认知行为疗法，但只有 40%的患者对这种一线治疗有反应。因此，必须进行新的治疗方法的研究。这篇综述重点介绍了锂作为一种潜在治疗策略对强迫症的潜在影响，以及锂发挥其有益特性的一些推测机制。锂药物可下调 GSK-3β，GSK-3β 是 WNT/β-连环蛋白通路的主要抑制剂。WNT/β-连环蛋白的激活可能与氧化应激、炎症和谷氨酸能通路的控制有关。未来的前瞻性临床试验可以集中在锂及其在 OCD 中的不同和多种相互作用上。
